Physician profile
Ashley Smith
NPI 1053911065
$1,121.55
in general payments reported to CMS, 2019-2025
19 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $186 · 2023: $353 · 2024: $344 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $265.12 | 2021-2024 | Bexsero, Pediarix |
| Ironshore Pharmaceuticals INC. | $175.87 | 2022-2024 | Jornay Pm |
| Corium, LLC | $134.69 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $100.50 | 2023-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $76.45 | 2021-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Sobi, INC | $48.86 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $47.28 | 2024 | Relexxii |
| Abiomed | $45.08 | 2024 | Impella |
| Collegium Pharmaceutical, INC. | $36.09 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $36.08 | 2025 | |
| Paratek Pharmaceuticals, INC. | $33.10 | 2025 | Xhance, Nuzyra |
| Qol Medical, LLC | $23.10 | 2023 | Sucraid |
| Avion Pharmaceuticals | $15.44 | 2024 | Methylphenidate Hydrochloride |
| Cranial Technologies, INC | $15.37 | 2024 | Doc Band |
| Alexion Pharmaceuticals, INC. | $15.09 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $14.54 | 2021 | |
| Amgen INC. | $13.89 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.67 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.